Glucagon Receptor Antagonist Peptides
Overview
Glucagon receptor antagonist peptides are a class of molecules designed to block the glucagon receptor and prevent glucagon-mediated hepatic glucose output. These peptides typically consist of modified glucagon analogs with substitutions that convert agonist activity to antagonism. The therapeutic rationale focuses on lowering blood glucose in type 2 diabetes by reducing hepatic gluconeogenesis and glycogenolysis. Structural modifications also enhance metabolic stability and receptor selectivity.
Key Research Findings
Early clinical studies of peptide-based glucagon receptor antagonists demonstrated glucose-lowering efficacy but raised concerns about hepatic steatosis and increased LDL cholesterol. Development efforts have largely shifted to small molecule antagonists and monoclonal antibodies due to pharmacokinetic limitations of peptide scaffolds. Preclinical models continue to validate the glucagon receptor as a target for diabetes, though no peptide antagonist has advanced to late-stage trials.
Subcutaneous injection
Research Phase
Interested in Glucagon Receptor Antagonist Peptides?
Find a verified provider experienced with Glucagon Receptor Antagonist Peptides protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Glucagon Receptor Antagonist Peptides ProviderRelated Peptides
Octreotide (Sandostatin)
FDA ApprovedA synthetic octapeptide analog of somatostatin with a substantially longer half-life (90 minutes IV, 6 hours subcutaneous vs. 2 minutes for native somatostatin). Octreotide binds somatostatin receptors (primarily SSTR2 and SSTR5) to inhibit the secretion of GH, glucagon, insulin, gastrin, secretin, VIP, and other GI hormones. It reduces splanchnic blood flow, GI motility, and exocrine pancreatic secretion.
Lanreotide (Somatuline Depot)
FDA ApprovedA synthetic octapeptide analog of somatostatin with high affinity for SSTR2 and moderate affinity for SSTR5 receptors. Lanreotide is formulated as a supersaturated solution that forms a drug depot at the injection site, providing sustained release over 4 weeks. It inhibits GH secretion, GI hormone release, and has direct antiproliferative effects on neuroendocrine tumor cells through cell cycle arrest and apoptosis induction.
Pasireotide (Signifor)
FDA ApprovedA multireceptor-targeted somatostatin analog with high binding affinity for SSTR1, SSTR2, SSTR3, and SSTR5, particularly notable for its 40-fold greater affinity for SSTR5 compared to octreotide. This receptor profile makes pasireotide uniquely effective in Cushing's disease, where corticotroph adenomas predominantly express SSTR5. Pasireotide suppresses ACTH secretion from pituitary corticotroph tumors, reducing cortisol production.
Plecanatide (Trulance)
FDA ApprovedA synthetic 16-amino acid peptide structurally related to uroguanylin, an endogenous intestinal peptide that regulates fluid and electrolyte homeostasis in the GI tract. Plecanatide activates guanylate cyclase-C (GC-C) receptors on intestinal epithelial cells in a pH-dependent manner, preferentially in the proximal small intestine where pH is slightly acidic. GC-C activation increases intracellular and extracellular cGMP, stimulating chloride and bicarbonate secretion while reducing visceral pain signaling.